Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

Please find enclosed a Press Release on

"Dr. Reddy's Laboratories announces the launch of Pyrimethamine Tablets USP, 25 mg, first-wave generic version of Daraprim

in the U.S. Market."

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code: RDY)

Classification | PUBLIC

Reddy's Laboratories announces the launch of

Pyrimethamine Tablets USP, 25 mg, first-wave generic version

of Daraprim in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. March 20, 2020-Dr.

Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr.

Reddy's") today announced the launch of Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic

version of Daraprim (pyrimethamine) Tablets, approved by the U.S. Food and Drug Administration (USFDA). This product

is the only AB-rated generic version Daraprim (pyrimethamine) Tablets approved by the USFDA.

"I am extremely proud of our teams at Dr. Reddy's

and Cerovene whose hard work and efforts, coupled with significant financial investments over the past seven years journey, have

helped bring this important product to market," says, Marc Kikuchi, Chief Executive Officer, North America Generics, Dr.Reddy's

Laboratories. "Our team's relentless pursuit of this difficult-to-procure reference drug and its active pharmaceutical

ingredients-in addition to recent actions from the USFDA (https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-

daraprim?utm_campaign=FDA%20approves%20first%20generic%20of%20Daraprim%20%28pyrimethamine%29%20tablets&utm_medium=email&utm_source=Eloqua)

-will benefit patients by providing a more affordable alternative to the brand." According to Kikuchi, the company

is offering this product at a substantial discount compared with the current brand price.

"The achievements of the Cerovene team to develop, file

and manufacture Pyrimethamine Tablets is a testament to our dedication and commitment to be able to provide this product to the

patients who need it most. We are pleased to collaborate with Dr. Reddy's as our commercial partner to make this important

drug available to patients in the U.S.," says, Ray DiFalco, Co-Founder and Vice President of Operations for Cerovene. "This

approval represents our continued commitment to develop and provide patients with greater choices and lower-cost alternatives for

prescription pharmaceuticals."

a recent press release (https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-daraprim?utm_campaign=FDA%20approves%20first%20generic%20of%20Daraprim%20%28pyrimethamine%29%20tablets&utm_medium=email&utm_source=Eloqua)

regarding the approval of this product, the USFDA

reiterated its commitment to improve "the efficiency of the generic drug development, review and approval process, as well

as closing loopholes that allow brand-name drug companies to delay the generic competition." The approval and launch of

Dr. Reddy's Pyrimethamine is a testament to the agency's actions, providing generic drug companies the opportunity

to compete fairly in the marketplace.

Pyrimethamine is indicated for the treatment of toxoplasmosis

when used conjointly with a sulfonamide, since synergism exists with this combination.

The Daraprim (pyrimethamine) brand had U.S.

sales of approximately $10 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

Dr. Reddy's Pyrimethamine Tablets USP, are available in

25 mg dose in bottle count sizes of 30 and 100.

What Important Information Should I Know About Pyrimethamine

Who Should Not Use Pyrimethamine Tablets USP, 25 mg?

What Should I Tell My Healthcare Provider Before Taking Pyrimethamine

Before taking Pyrimethamine Tablets, tell your doctor if you:

What Are the Adverse Reactions of Pyrimethamine Tablets USP,

Call your doctor or get emergency help right away if you develop:

Anorexia and vomiting may also occur.

What Should I Avoid While Taking Pyrimethamine Tablets USP,

Please refer to the Package Insert for full prescribing information

for Pyrimethamine Tablets USP, 25 mg.

For more information, ask your healthcare provider or pharmacist.

You are encouraged to report negative side effects of prescription drugs. To report suspected side effects, call Dr. Reddy's

Laboratories Medical Information Hotline at 1-888-DRL-DRUG (1-888-375-3784) or via email to medinfo@drreddys.com or contact the

USFDA at 1-800-FDA-1088 (1-800-332-1088) or online at http://www.fda.gov/safety/medwatch.

Indication and Usage for Pyrimethamine Tablets USP, 25 mg

Please see the full prescribing information.

Daraprim is a trademark owned by or licensed to Vyera Pharmaceuticals,

*IQVIA Retail and Non-Retail MAT January 2020.

About Cerovene: Cerovene, Inc., a privately held

company, is engaged in the research, development and manufacturing of pharmaceuticals. The company's expertise in both solid

and liquid dosage products, extends across a range of drug delivery technologies, including Pulse Release, Delayed and Sustained

Release, Extended Release, Sustained Zero-Order Release, Matrix-Hydrogel Controlled Released, Enteric Coated, Tablet in Capsule

and Coated Capsules. Cerovene developes, files and manufacturers both Branded and Generic pharmaceutical products. For more information

visit www.cerovene.com

About Dr. Reddy's: Dr. Reddy's Laboratories

Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative

medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics

and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical

services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,

diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets

include - USA, India, Russia & CIS countries, and Europe. For more information, log on to:www.drreddys.com

Disclaimer: This press release may include statements

of future expectations and other forward-looking statements that are based on the management's current views and assumptions

and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially

from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context,

the words "may", "will", "should", "expects", "plans", "intends",

"anticipates", "believes", "estimates", "predicts", "potential", or "continue"

and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from

those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,

credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events

(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes

in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization

, including related integration issues.

The company assumes no obligation to update any information